Several researchers have developed powerful methods for DNA sequencing, but in the Sanger method only, you will be able to make accurate long stretch of sequence of DNA. Sanger method is the only technology that has been used successfully for the sequence of the genome of the animal, including the human genome and the entire plant, but limited usefulness in intensive, as a tool for routine , sequence of human clinical samples such as those from malignant tissue like this that are using the demand for laboratory technicians and process of expensive reagents and equipment. These restrictions, as a result of the new microfluidic device colleague Richard Mathies, Ph.D., from the University of California, Berkeley have developed, however, there may be room for discussion. This new device, every step of the Sanger on which you can lab-on-a-chip is to sequence a permanent base of more than 500 with an accuracy of 99% is included.

Writing in the Proceedings of the National Academy of Sciences, they in order to create a system that is independent of double for DNA sequencing, and his colleagues Matisse, the polymer polydimethylsiloxane biocompatible and glass get (PDMS) you will learn how to build a symmetrical bio processor using a combination of. The use of these materials, researchers to produce a system with the complexity of the process, the unprecedented performance of the microfluidic device and the like. The device, the reaction chamber 250 nanoliters include it is possible to heat treatment gel using cycle DNA affinity capture, microvalve and reagent dispensing chamber, the gel-filled capillary electrophoresis flow channels and pumping system. Combinations of these features of the microfluidic device reduces the amount of reagents required for Sanger sequencing considerably. New device is fully integrated and, most importantly, to automate the process Sanger.

It is preliminary, but researchers, further, this device is believed to reduce the use of reagents, and can improve the design. Ultimately, the researchers believe that you use 800-fold-DNA sequencing reagents and 400 times lower than the current technology will be the next generation microfluidic Sanger sequencing chip. Pointed out that it is possible to biomedical applications various single nucleotide polymorphisms will be useful for the various components of Sanger sequence their screening a tumor biopsy and genotyping, etc. (SNP) screening, researchers also have. Currently, Bio-Technology Co., Ltd. of the microchip, Dublin, CA is working on the development of commercial devices using this technology.